Floatz logo

Venetoclax

Measurable Residual Disease (MRD)

Nanfang Hospital, Southern Medical UniversitySmall moleculePhase 2/3Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

3 Active assets in the Measurable Residual Disease (MRD) cohort.

Asset / SponsorPhaseRating
Sorafenib
Nanfang Hospital, Southern Medical University
Phase 2/3B
Blinatumomab
Hospital Universitario Dr. Jose E. Gonzalez
Phase 2CCC
DEXAMETHASONE
Hospital Universitario Dr. Jose E. Gonzalez
Phase 2CCC

Same molecule, other indications

Venetoclax is also rated in:

Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 PositiveDormant
BBB
Indicative ·
72 / 100
View asset →
chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
BB
Indicative ·
70 / 100
View asset →
myeloid neoplasmDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →